FDA declines to approve Summit lung cancer drug after survival miss
Summit said the FDA issued a complete response letter for ivonescimab in EGFR-mutated NSCLC after overall survival in HARMONi did not reach statistical significance.
What's new
- New headline Was: “US FDA declines to approve Summit lung cancer drug after trial misses key survival goal”
- Our desk filed its story